A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia

NCT06709131 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

24

Enrollment

OTHER

Sponsor class

Stopped Product manufacturing process improvement

Conditions

Relapsed/Refractory Acute Myeloid Leukemia(AML)

Interventions

DRUG: CAR-T cells（ chimeric antigen receptor T cells）

Sponsor

He Huang